← Literature

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

rct • 2025 • ID: 40544432

High Confidence RCT

Primary source: [Open]

Linked compounds: cagrilintidesemaglutide

Outcomes summary

Randomized trial evaluating cagrilintide combined with semaglutide in adults with overweight/obesity and type 2 diabetes, reporting cardiometabolic and weight-related outcomes.

Limitations

Generalizability depends on population and comparator; interpretation depends on studied doses, estimands, and trial duration.

Notes

Primary source: PMID 40544432.